Bausch & Lomb Incorporated develops, manufactures, and markets eye care products. Its products contact lens with wearing modalities; lens care products, such as chemical disinfectants for soft contact lenses, as well as Boston line of products for cleaning GP contact lenses; and prescription and over-the-counter pharmaceutical medicines to treat a range of eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases. The company also provides a line of Rx products, which include the antibacterial eye drops, the steroid eye drops, and retinal diseases treatment products; and cataract and vitreoretinal surgery products, such as intraocular lenses and deliver...
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807
Founded in 1853
Bausch + Lomb Launches of EZ-24 Easy-Load Lens Delivery System for SofPort Advanced Optics Intraocular Lenses
Jul 13 16
Bausch + Lomb announced the launch of the EZ-24 Easy-Load lens delivery system, which is designed exclusively for use with the SofPort Advanced Optics (AO) intraocular lens (IOL). The EZ-24 Easy-Load lens delivery system facilitates smooth and easy delivery of the SofPort IOL through a 2.4mm incision. This new delivery system features a smooth oval tip designed for ease of wound entry, reliability and control. Combining the benefits of sterile, single-use "no-touch" lens loading design with Bausch + Lomb's proprietary planar delivery, the device facilitates direct placement of the SofPort IOL (LI61AO and LI61SE) into the capsular bag, minimizing tissue trauma and related potential complications compared to traditional IOL insertion through primary incisions in the cornea. Additionally, its M-folded delivery gives the physician excellent control on lens delivery in the bag.
Bausch + Lomb and Nicox S.A. Announces the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results
Jul 6 16
Bausch + Lomb and Nicox S.A. announced that the results of a Phase 3 study for latanoprostene bunod (LBN) ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology. LBN 0.024% is an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily for patients with open angle glaucoma (OAG) or ocular hypertension (OHT). In the eye, LBN is metabolized to two moieties. The first, latanoprost acid, is an F2a prostaglandin analog, while the second, butanediol mononitrate, releases nitric oxide, which activates the soluble guanylate cyclase–cyclic guanosine-3',5'-monophosphate signaling pathway. Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. The results of this study, called LUNAR, demonstrated that LBN 0.024% administered once daily (QD) in the evening was not only non-inferior to timolol maleate 0.5% dosed twice daily (BID) in subjects with OAG or OHT over 3 months of treatment, but also provided significantly greater IOP reduction (P=0.025) at all but the earliest time point evaluated. If approved, this therapy would offer a new therapeutic alternative for physicians and their patients with open angle glaucoma or ocular hypertension. A prospective, double-masked, parallel group, clinical trial, LUNAR compared the IOP lowering effect of LBN 0.024% with timolol maleate 0.5% in adults with OAG or OHT. Subjects from 46 clinical sites in the U.S. and Europe were randomized to administer LBN QD in the evening or timolol BID for 3 months. Intraocular pressure was measured at 9 time points (Week 2, Week 6 and Month 3; 8am, 12pm and 4pm each visit). The primary objective was to demonstrate non-inferiority to timolol, while the secondary objective was to demonstrate superiority. The results of this study showed that mean IOP was significantly lower in the LBN 0.024% group than in the timolol 0.05% group at all time points (range 17.7 - 18.7 mm Hg for LBN 0.024%; 18.8-19.6 mm Hg for timolol 0.5%;P=0.025) except for at Week 2, 8 am (19.2 mm Hg for LBN 0.024% vs 19.6 mm Hg for timolol 0.5%; P=0.216). These differences corresponded to a reduction from baseline ranging from 29.1% to 32.1% in the LBN 0.024% group and 25.2% to 28.7% in the timolol group. Adverse events, though uncommon, were slightly higher in the LBN group. They included conjunctival hyperemia, eye irritation, and eye pain and were mostly mild-to-moderate in severity. A second similarly designed study, published in the May issue of Ophthalmology, also demonstrated the efficacy of LBN 0.024% for IOP lowering. In this randomized, controlled, multicenter, double-masked, parallel-group, non-inferiority clinical study, called APOLLO, the primary efficacy end point was IOP in the study eye measured at the same 9 assessment time points as LUNAR. Results showed that the mean IOP in the study eye was significantly lower in the LBN 0.024% group (range, 17.8-18.7 mm Hg) than in the timolol 0.5% group (range, 19.1-19.8 mm Hg) at all 9 efficacy time points assessed.
Valeant Pharmaceuticals May Sell Bausch & Lomb
Jun 29 16
Valeant Pharmaceuticals International was previously rumored to be selling Bausch & Lomb Incorporated for reducing its debt. However, David Maris of Wells Fargo believes a possible sale of Bausch & Lomb may not solve all Valeant's debt problems.